Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group

Documenti analoghi

• Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry
  di: Konrad van der Zwet, et al.
  Pubblicazione: (2024)
• Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry
  di: Aikaterini Michalopoulou, et al.
  Pubblicazione: (2025)
• Impact of Family History of Haemophilia on Diagnosis, Management and Outcomes in Severe Haemophilia
  di: Ana Mendoza, et al.
  Pubblicazione: (2025)
• Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence
  di: Gili Kenet, et al.
  Pubblicazione: (2024)
• Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
  di: Annika Mårtensson, et al.
  Pubblicazione: (2024)